MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ejca.2015.12.029

Медицинская библиотека · European journal of cancer (Oxford, England : 1990) · 2016

Relationship between imatinib trough concentration and outcomes in the treatment of advanced gastrointestinal stromal tumours in a real-life setting.

Bouchet Stéphane, Poulette Sylvie, Titier Karine, Moore Nicholas, Lassalle Régis, Abouelfath Abdelilah, Italiano Antoine, Chevreau Christine, Bompas Emmanuelle, Collard Olivier, Duffaud Florence, Rios Maria, Cupissol Didier, Adenis Antoine, Ray-Coquard Isabelle, Bouché Olivier, Le Cesne Axel, Bui Binh, Blay Jean-Yves, Molimard Mathieu

СтатьяМногоцентровое исследованиеНаблюдательное исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

Imatinib has dramatically improved the prognosis of advanced gastrointestinal stromal tumours (GISTs). Clinical trial data showed that patients with trough imatinib plasma concentrations (Cmin) below 1100 ng/ml (quartile 1) had shorter time to progression, but no threshold has been defined. The main objective of this study was to investigate in advanced GIST whether a Cmin threshold value associated with a longer progression-free survival (PFS) could be specified. This would be the first step leading to therapeutic drug monitoring of imatinib in GIST.

PATIENTS AND

METHODS

Advanced GIST patients (n=96) treated with imatinib 400 mg/d (41 stomach, 34 small bowel, and 21 other primary site localisations) were prospectively included in this real-life setting study. Routine plasma level testing imatinib (Cmin) and clinical data of were recorded prospectively.

RESULTS

Small bowel localisation was associated with an increased relative risk of progression of 3.09 versus stomach localisation (p=0.0255). Mean Cmin (±standard deviation) was 868 (±536) ng/ml with 75% inter-individual and 26% intra-patient variability. A Cmin threshold of 760 ng/ml defined by log-rank test was associated with longer PFS for the whole population (p=0.0256) and for both stomach (p=0.043) and small bowel (p=0.049) localisations when analysed separately. Multivariate Cox regression analysis found that Cmin above 760 ng/ml was associated with 65% reduction risk of progression (p=0.0271) in the whole population independently of the anatomical localisation.

CONCLUSION

Concentration of imatinib significantly influences duration of tumour control treatment in GIST patients with a Cmin threshold of 760 ng/ml associated with prolonged PFS in real-life setting.

Для цитирования: Bouchet Stéphane, Poulette Sylvie, Titier Karine, Moore Nicholas, Lassalle Régis, Abouelfath Abdelilah, Italiano Antoine, Chevreau Christine, Bompas Emmanuelle, Collard Olivier, Duffaud Florence, Rios Maria, Cupissol Didier, Adenis Antoine, Ray-Coquard Isabelle, Bouché Olivier, Le Cesne Axel, Bui Binh, Blay Jean-Yves, Molimard Mathieu. Relationship between imatinib trough concentration and outcomes in the treatment of advanced gastrointestinal stromal tumours in a real-life setting.. European journal of cancer (Oxford, England : 1990). 2016. DOI: 10.1016/j.ejca.2015.12.029.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.